Sun, Apr 20, 2014, 1:57 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Geron Corporation (GERN) Message Board

gosmokeadoobie 30 posts  |  Last Activity: Mar 2, 2014 12:42 AM Member since: Nov 27, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • gosmokeadoobie gosmokeadoobie Mar 2, 2014 12:42 AM Flag

    mpnforum
    December-January 2014
    Betting the farm on imetelstat It just might work.

    necrocorpser - an informative read. thanks

  • gosmokeadoobie gosmokeadoobie Mar 1, 2014 11:53 PM Flag

    Received: July 19, 2013
    Telomerase Inhibitor Imetelstat (GRN163L) Limits the Lifespan of Human Pancreatic Cancer Cells

    "Telomerase is required for the unlimited lifespan of cancer cells. The vast majority of pancreatic adenocarcinomas overexpress telomerase activity and blocking telomerase could limit their lifespan. GRN163L (Imetelstat) is a lipid-conjugated N3'→P5' thio-phosphoramidate oligonucleotide that blocks the template region of telomerase. The aim of this study was to define the effects of long-term GRN163L exposure on the maintenance of telomeres and lifespan of pancreatic cancer cells. Telomere size, telomerase activity, and telomerase inhibition response to GRN163L were measured in a panel of 10 pancreatic cancer cell lines. The cell lines exhibited large differences in levels of telomerase activity (46-fold variation), but most lines had very short telomeres (2-3 kb in size). GRN163L inhibited telomerase in all 10 pancreatic cancer cell lines, with IC50 ranging from 50 nM to 200 nM. Continuous GRN163L exposure of CAPAN1 (IC50 = 75 nM) and CD18 cells (IC50 = 204 nM) resulted in an initial rapid shortening of the telomeres followed by the maintenance of extremely short but stable telomeres. Continuous exposure to the drug eventually led to crisis and to a complete loss of viability after 47 (CAPAN1) and 69 (CD18) doublings. Crisis In these cells was accompanied by activation of a DNA damage response (γ-H2AX) and evidence of both senescence (SA-β-galactosidase activity) and apoptosis (sub-G1 DNA content, PARP cleavage). Removal of the drug after long-term GRN163L exposure led to a reactivation of telomerase and re-elongation of telomeres in the third week of cultivation without GRN163L. These findings show that the lifespan of pancreatic cancer cells can be limited by continuous telomerase inhibition. These results should facilitate the design of future clinical trials of GRN163L in patients with pancreatic cancer."

    necrocorpser - nice find!

  • Reply to

    Why would Geron not want "fast-track"?

    by lws2000 Feb 27, 2014 1:04 PM
    gosmokeadoobie gosmokeadoobie Feb 28, 2014 1:49 PM Flag

    sidesaddlexxx - FDA approval of imetelstat is the goal but geron's approach has to be well thought out to avoid a shot on goal. geron's approach will be the difference between winning and losing.

  • Reply to

    Why would Geron not want "fast-track"?

    by lws2000 Feb 27, 2014 1:04 PM
    gosmokeadoobie gosmokeadoobie Feb 27, 2014 6:16 PM Flag

    just look at what happened to aveo. this company pushed a drug for liver cancer and management thought they had approval in the bage, but the FDA shot them down after the phase 3 trial results didn't pass muster.

  • gosmokeadoobie gosmokeadoobie Feb 27, 2014 6:00 PM Flag

    that's the purpose of the upcoming phase 2 MF trial. to refine the application of imetelstat in MF.

    chip, tefferi & crew have a much better understanding of the subtypes of MF that will and will not respond to imetelstat, so it will be very interesting to see how the statistics evolve from this trial.

  • Reply to

    adr fee

    by kevator Feb 25, 2014 6:57 AM
    gosmokeadoobie gosmokeadoobie Feb 26, 2014 3:35 AM Flag

    the adr fee is a scam and jpmorgan knows this!

  • gosmokeadoobie gosmokeadoobie Feb 26, 2014 3:27 AM Flag

    the TIM contract must come with a decent margin because combes is looking to get out of the third gen line of business ... or maybe he's planting the seed for a future LTE contract.

  • Reply to

    Universal Metastasis Inhibitor

    by nom_de_plune Feb 20, 2014 3:24 PM
    gosmokeadoobie gosmokeadoobie Feb 26, 2014 2:48 AM Flag

    bgmarcks - have you heard of non-small-cell lung NSCL cancer? that may be one of the solid tumor studies to which you refer? geron dropped all solid tumor studies a couple years ago, but that's not because grn163l lacks efficacy, no.

    geron hired a well experienced CEO at the end of 2011. john scarlett brought a fresh perspective to this cash burning enterprise. within a few months scarlett realized that grn163l was the future, so he cleared the deck.

    imetelstat works on cancers with short telomeres and blood disorders have the shortest telomeres. as with MF, imetelstat is effective with a subgroup of this type of cancer. some solid tumors have short telomeres as well. but like blood cancers, solid tumors have subtypes, too.

    imetelstat shows promise in NSCL cancer along with other solid tumors with short telomeres, but the company does not have the cash to finance such pursuits.

  • Reply to

    Focus, Focus, FOCUS!!!

    by blackmarango Feb 24, 2014 11:41 AM
    gosmokeadoobie gosmokeadoobie Feb 25, 2014 8:04 PM Flag

    patients with MF that can NOT afford grn163l will not be denied treatment because they will be given jakafi. so put that in your pipe and smoke it.

  • Reply to

    Focus, Focus, FOCUS!!!

    by blackmarango Feb 24, 2014 11:41 AM
    gosmokeadoobie gosmokeadoobie Feb 25, 2014 6:20 PM Flag

    mainecoastlover1 - you're too funny! but with $472 626 on the line, your cynicism is warranted.

    however, even a self declared fringe lunatic investors such as yourself needs to be cognizant of what drives a company's value.

    so what drives value? revenue. yes, revenue that grows over time. but it isn't that simple because, as case in point, geron has little to no revenue. however, with geron it is the concept of potential future revenues that drives this company's value.

    now, the question at hand is, what good are revenues when the associated costs are exorbitantly high? ah, there in lies the problem.

    let's run through an example: if a patient has MF but has no way to pay for an over priced therapy, then that patient isn't going to be treated with imetelstat. yes, it's that simple.

  • Reply to

    Focus, Focus, FOCUS!!!

    by blackmarango Feb 24, 2014 11:41 AM
    gosmokeadoobie gosmokeadoobie Feb 25, 2014 3:20 AM Flag

    the cost of imetelstat is an issue. why this drug's cost has never been addressed can be viewed with skepticism. why chief financial officer Olivia K. Bloom has never broken out this cost is suspicious. but it could be that she is just plain lazy, so why is geron paying her $450,000? because figuring out the manufacturing cost of a short strand of molecules is common practice in the biotech industry. this lack of transparency is an issue.

  • gosmokeadoobie gosmokeadoobie Feb 19, 2014 2:02 PM Flag

    fyi - gosmokeadoobie owns nearly 35,000 shares of geron so raising awareness of the relatively high manufacturing cost of grn163l is not meant as a negative ... but more a reality check.

  • gosmokeadoobie gosmokeadoobie Feb 19, 2014 1:38 PM Flag

    jackdaw605 - then get crackin' on it you nimwit.

  • gosmokeadoobie gosmokeadoobie Feb 19, 2014 1:45 AM Flag

    June 26, 2006

    Geron Corporation today announced the publication of novel chemical methods that reduce the number of chemical steps and cost of synthesizing the monomer building blocks of its patented N3'-P5' thiophosphoramidate oligonucleotide compounds, including its lead anti-cancer drug, GRN163L.

    Presented in a paper published in the June 26 issue of Tetrahedron Letters, the new approach utilizes starting materials that contain a nitrogen in the key (3') position, reducing the number of steps to achieve the final "activated 3'-amino" monomer building blocks from seven-ten to two-three. This increases the yield of the overall reaction and SIGNIFICANTLY REDUCES THE COST of the building blocks as well as the cost of the final oligonucleotide products.

  • gosmokeadoobie gosmokeadoobie Feb 19, 2014 1:18 AM Flag

    mainecoastlover1 - if you read the prospectus from which this "conjecture" was lifted, there would have been no need for you to fiddle about with your reply. -take another puff

  • PROSPECTUS SUPPLEMENT
    date of this prospectus supplement is January 30, 2014
    22,500,000 Shares of Geron

    Imetelstat is likely to be more expensive to manufacture than most other treatments currently available today or that may be available in the future.

    The commercial cost of manufacturing imetelstat will need to be significantly lower than our current costs in order for imetelstat to become a commercially successful product.

    Oligonucleotides are relatively large molecules produced using complex chemistry, and the cost of manufacturing an oligonucleotide like imetelstat is greater than the cost of making typical small-molecule drugs.

    Our present imetelstat manufacturing processes are conducted at a relatively modest scale appropriate for our ongoing Phase 2 clinical trials and investigator-sponsored trials for which we provide clinical drug supply.

    We may not be able to achieve sufficient scale increases or cost reductions necessary for successful commercial production of imetelstat.

    Additionally, given the complexities of our manufacturing processes, the resulting costs that we incur to conduct our clinical trials may be higher than for other comparable treatments, requiring us to expend relatively larger amounts of cash to complete our clinical trials, which would negatively impact our financial condition and could increase our need for additional capital.

  • Reply to

    Alcatel-Lucent

    by rskrwrd Feb 17, 2014 3:16 PM
    gosmokeadoobie gosmokeadoobie Feb 17, 2014 4:21 PM Flag

    whether quarterly or annually wireless revenues continue to grow.

    Wireless Division__ Y2013__Q4'13__Q3'13__Q2'13__Q1'13__ Y2012__Q4'12__ Q3'12__Q2'12__Q1 '12
    Revenues________€4,510__1,240__ 1,196__1,062__1,012__ €4,151__1,123 __1,062__1,035___931

    Revenues for the Wireless Access division were Euro 1,240 million, an increase of 15.0% at constant exchange rates from Q4 2012, with LTE revenues MORE THAN DOUBLING, driven by large deployment activities in the US and China.

  • Geron Prospectus Supplement dated January 29, 2014

    We believe that inhibiting telomerase may be an attractive approach to treating cancer because it may limit the proliferative capacity of malignant cells. We and others have observed in various in vitro and rodent tumor models that inhibiting telomerase results in telomere shortening and arrests uncontrolled malignant cell proliferation and tumor growth. In vitro studies have suggested that tumor cells with short telomeres may be especially sensitive to the anti-proliferative effects of inhibiting telomerase. Our non-clinical data also suggest that inhibiting telomerase is particularly effective at limiting the proliferation of malignant progenitor cells, which have high levels of telomerase and are believed to be important drivers of tumor growth and progression.

    Many hematologic malignancies, such as polycythemia vera, or PV, ET and MF, are KNOWN TO ARISE FROM MALIGNANT PROGENITOR CELLS IN THE BONE MARROW THAT EXPRESS HIGHER TELOMERASE ACTIVITY AND HAVE SHORTER TELOMERES when compared to normal healthy cells. These disease characteristics support telomerase as a rational and potentially specific oncology target for the use of imetelstat, a potent and specific inhibitor of telomerase.

  • Reply to

    About Brokaw and Tefferi

    by bjlikey Feb 11, 2014 8:09 PM
    gosmokeadoobie gosmokeadoobie Feb 11, 2014 9:40 PM Flag

    the link between short telomeres and imetelstat's efficacy is too established to be ignored.

  • Reply to

    Q4 2013 Wireless Key highlight:

    by gosmokeadoobie Feb 8, 2014 9:41 PM
    gosmokeadoobie gosmokeadoobie Feb 9, 2014 2:22 PM Flag

    whether quarterly or annually wireless revenues continue to grow.

    Wireless Division__ Y2013__Q4'13__Q3'13__Q2'13__Q1'13__ Y2012__Q4'12__ Q3'12__Q2'12__Q1 '12
    Revenues________€4,510__1,240__ 1,196__1,062__1,012__ €4,151__1,123 __1,062__1,035___931

GERN
1.94-0.03(-1.52%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.